RECENT ADVANCES IN THE PREPARATION OF PLASMA-DERIVED AND RECOMBINANT COAGULATION FACTOR-VIII

被引：3

作者：

BRAY, GL

机构：

[1] Pediatrics (Hematology/Oncology) George Washington University School of Medicine Washington

[2] Hemophilia Program Children's National Medical Center Washington

来源：

JOURNAL OF PEDIATRICS | 1990年 / 117卷 / 03期

关键词：

D O I：

10.1016/S0022-3476(05)81107-2

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

[No abstract available]

引用

页码：503 / 507

页数：5

共 50 条

[1] INHIBITOR QUESTIONS - PLASMA-DERIVED FACTOR-VIII AND RECOMBINANT FACTOR-VIII
BRAY, G
ANNALS OF HEMATOLOGY, 1994, 68 : S29 - S34
[2] RELATION OF ACTIVATED FACTOR-VIII TO THE POTENCY IN FACTOR-VIII CONCENTRATES, COMPARISON OF PLASMA-DERIVED AN RECOMBINANT FACTOR-VIII
MINAMIYAMA, T
ITO, Y
OGURI, S
KOBAYASHI, K
TAKEDA, M
THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 942 - 942
[3] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIII ARE IMMUNOLOGICALLY DISTINCT IN IN-VITRO ASSAYS
GILLES, JGG
SAINTREMY, JMR
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1213 - 1213
[4] VIRAL SAFETY ISSUES - PLASMA-DERIVED FACTOR-VIII
BERNTORP, E
ANNALS OF HEMATOLOGY, 1994, 68 : S35 - S36
[5] ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES
O'Day, K.
Runken, M. C.
Meyer, K. L.
Spears, J. B.
VALUE IN HEALTH, 2017, 20 (05) : A216 - A217
[6] EPITOPE SPECIFICITY OF INHIBITOR ANTIBODIES FROM PATIENTS TREATED WITH RECOMBINANT OR PLASMA-DERIVED FACTOR-VIII
SCANDELLA, D
CORTER, S
GOMPERTS, E
HURST, D
ESMON, P
THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 557 - 557
[7] Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
Mannucci, Pier Mannuccio
BLOOD TRANSFUSION, 2010, 8 (04) : 288 - 291
[8] Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates
Lin, Y
Yang, X
Chevrier, MC
Craven, S
Barrowcliffe, TW
Lemieux, R
Ofosu, FA
HAEMOPHILIA, 2004, 10 (05) : 459 - 469
[9] Factor VIII safety: plasma-derived versus recombinant products
Gringeri, Alessandro
BLOOD TRANSFUSION, 2011, 9 (04) : 366 - 370
[10] Plasma-derived versus recombinant factor VIII for the treatment of hemophilia A
Kasper, CK
VOX SANGUINIS, 1996, 70 : 17 - 20

← 1 2 3 4 5 →